# STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Source: https://onco.cc/trials/nct06975293/  
OnCo record `nct06975293` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab in sarcomas and uterine sarcoma, run by STORM Therapeutics LTD, now recruiting.

## Summary

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas is a phase 1/2 interventional study registered as NCT06975293 by STORM Therapeutics LTD, with 107 participants planned, started 2025-05-05 and due to reach its primary completion in 2027-12-29. Interventions recorded: STC-15 in combination with toripalimab and STC-15 monotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06975293
- Phase: 1/2
- Setting: Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- Sponsor: STORM Therapeutics LTD
- Enrolled: 107

## Sources

- ClinicalTrials.gov NCT06975293: https://clinicaltrials.gov/study/NCT06975293

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Uterine sarcoma](https://onco.cc/cancers/uterine-sarcoma/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Coherus BioSciences](https://onco.cc/companies/coherus/)

---
JSON: https://onco.cc/api/v1/entities/nct06975293.json